RCUS — Arcus Biosciences Share News
0.000.00%
Last trade - 00:00- $2.91bn
- $2.30bn
- $247.00m
Brief: Arcus Biosciences Q3 Revenue USD 20 Million Vs. IBES Estimate USD 24.6 Million
Brief: Arcus Bioscience Announces First Overall Survival Results From Phase 2 Edge-Gastric Study
Brief: Arcus Biosciences Presents New Data for its HIF-2a Inhibitor Casdatifan
Brief: Arcus Biosciences Q2 Revenue USD 152 Million Vs. IBES Estimate USD 31.5 Million
U.S. STOCKS ON THE MOVE-Tesla, AbbVie, McDonald's
Arcus Biosciences up after FDA's 'orphan drug' tag for pancreatic cancer treatment
Brief: Arcus Says Initial Data From The Arc-20 Study Of Casdatifan Plus Cabozantinib Showed Nearly Half Of Patients With Metastatic Kidney Cancer Had A Confirmed Response
Arcus Biosciences Inc reports results for the quarter ended March 31 - Earnings Summary
U.S. STOCKS ON THE MOVE-AerCap Holdings, Salesforce, Emcor Group
U.S. STOCKS ON THE MOVE-Cheesecake Factory, SiriusPoint, Arcutis Biosciences
Arcus Biosciences gains after H.C. Wainwright upgrades to "buy"
Arcus Biosciences Inc reports results for the quarter ended December 31 - Earnings Summary
Arcus Biosciences Inc expected to post a loss of $1.25 a share - Earnings Preview
Brief: Arcus Biosciences To Offer 13.6 Million Shares At $11.00 Per Share
U.S. STOCKS ON THE MOVE-General Mills, Meta Platforms, Domino's Pizza
U.S. STOCKS ON THE MOVE-Watsco, Septerna, Nike
U.S. STOCKS ON THE MOVE-Wynn Resorts, Southwest Airlines, Extreme Networks
Arcus Biosciences falls on pricing $150 mln stock offering at 16% discount
Arcus Biosciences Inc reports results for the quarter ended in September 30 - Earnings Summary